Cargando…

Current and Future Biomarkers for Immune Checkpoint Inhibitors in Head and Neck Squamous Cell Carcinoma

With the introduction of immunotherapy, significant improvement has been made in the treatment of head and neck squamous cell carcinoma (HNSCC). However, only a small subset of patients with HNSCC benefit from immunotherapy. The current biomarker, a programmed cell death protein ligand 1 (PD-L1) exp...

Descripción completa

Detalles Bibliográficos
Autores principales:	Park, Jong Chul, Krishnakumar, Hari N., Saladi, Srinivas Vinod
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9221564/ https://www.ncbi.nlm.nih.gov/pubmed/35735443 http://dx.doi.org/10.3390/curroncol29060334

Ejemplares similares

Protocol for Bulk-ATAC sequencing in head and neck squamous cell carcinoma
por: Chen, Nana, et al.
Publicado: (2023)

Immune biomarkers of response to immune-checkpoint inhibitors in head and neck squamous cell carcinoma
por: Oliva, M, et al.
Publicado: (2019)

Molecular Biomarkers of Malignant Transformation in Head and Neck Dysplasia
por: Ranganath, Kushi, et al.
Publicado: (2022)

Overcoming Resistance to Immune Checkpoint Inhibitors in Head and Neck Squamous Cell Carcinomas
por: dos Santos, Lucas V., et al.
Publicado: (2021)

Immune Checkpoints Pathways in Head and Neck Squamous Cell Carcinoma
por: Veigas, Florencia, et al.
Publicado: (2021)

Exploration of Feasible Immune Biomarkers for Immune Checkpoint Inhibitors in Head and Neck Squamous Cell Carcinoma Treatment in Real World Clinical Practice
por: Wang, Hui-Ching, et al.
Publicado: (2020)

Prognostic Value of Inflammatory and Nutritional Biomarkers of Immune Checkpoint Inhibitor Treatment for Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
por: Sakai, Akihiro, et al.
Publicado: (2023)

Immune checkpoint pathways in immunotherapy for head and neck squamous cell carcinoma
por: Mei, Zi, et al.
Publicado: (2020)

Outcomes and Biomarkers of Immune Checkpoint Inhibitor Therapy in Patients with Refractory Head and Neck Squamous Cell Carcinoma: KCSG HN18-12
por: Lee, Yun-Gyoo, et al.
Publicado: (2021)

Current landscape and future directions of biomarkers for predicting responses to immune checkpoint inhibitors
por: Zhu, Yingming, et al.
Publicado: (2018)

Immuno-Oncological Biomarkers for Squamous Cell Cancer of the Head and Neck: Current State of the Art and Future Perspectives
por: De Keukeleire, Stijn J., et al.
Publicado: (2021)

Current status and future potential of predictive biomarkers for immune checkpoint inhibitors in gastric cancer
por: Kang, Byung Woog, et al.
Publicado: (2020)

Present and Future of EGFR Inhibitors for Head and Neck Squamous Cell Cancer
por: Baba, Yuh, et al.
Publicado: (2012)

Combining Radiation and Immune Checkpoint Blockade in the Treatment of Head and Neck Squamous Cell Carcinoma
por: Manukian, Gregor, et al.
Publicado: (2019)

Immune checkpoint inhibitors in head and neck squamous cell carcinoma: A systematic review of phase-3 clinical trials
por: Poulose, Jissy Vijo, et al.
Publicado: (2022)

Combination therapy with oncolytic viruses and immune checkpoint inhibitors in head and neck squamous cell carcinomas: an approach of complementary advantages
por: Dong, Hui, et al.
Publicado: (2023)

Therapeutic Approaches With Immune Checkpoint Inhibitors in Head and Neck Cancers and the Role of PD-L1 as a Biomarker
por: Oualla, Karima, et al.
Publicado: (2021)

Cancer Immunotherapy with Immune Checkpoint Inhibitors-Biomarkers of Response and Toxicity; Current Limitations and Future Promise
por: Healey Bird, Brian, et al.
Publicado: (2022)

Immune Checkpoint Inhibitor Toxicity in Head and Neck Cancer: From Identification to Management
por: Wang, Haiyang, et al.
Publicado: (2019)

Rational Combinations of Targeted Therapy and Immune Checkpoint Inhibitors in Head and Neck Cancers
por: Chai, Annie Wai Yeeng, et al.
Publicado: (2022)

Immune Checkpoint Inhibition in Head and Neck Cancer
por: Forster, Martin David, et al.
Publicado: (2018)

Patterns of Response to Immune Checkpoint Inhibitors in Association with Genomic and Clinical Features in Patients with Head and Neck Squamous Cell Carcinoma (HNSCC)
por: Economopoulou, Panagiota, et al.
Publicado: (2021)

Clinical Outcomes of Cetuximab and Paclitaxel after Progression on Immune Checkpoint Inhibitors in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
por: Suzuki, Shinsuke, et al.
Publicado: (2021)

Clinical-genomic determinants of immune checkpoint blockade response in head and neck squamous cell carcinoma
por: Valero, Cristina, et al.
Publicado: (2023)

PD-L1 expression in the microenvironment and the response to checkpoint inhibitors in head and neck squamous cell carcinoma
por: Evrard, D., et al.
Publicado: (2020)

Current state and future of photodynamic therapy for the treatment of head and neck squamous cell carcinoma
por: Mimikos, Christina, et al.
Publicado: (2016)

Advances in T-cell checkpoint immunotherapy for head and neck squamous cell carcinoma
por: Qi, Xinmeng, et al.
Publicado: (2017)

Predictive Value of Skeletal Muscle Mass in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma Patients Treated With Immune Checkpoint Inhibitors
por: Arribas, Lorena, et al.
Publicado: (2021)

Cardiotoxicity associated with immune checkpoint inhibitors: Current status and future challenges
por: Gan, Lu, et al.
Publicado: (2022)

Characterization of tumor-associated T-lymphocyte subsets and immune checkpoint molecules in head and neck squamous cell carcinoma
por: Lechner, Axel, et al.
Publicado: (2017)

Next-generation sequencing identifies CDKN2A alterations as prognostic biomarkers in recurrent or metastatic head and neck squamous cell carcinoma predominantly receiving immune checkpoint inhibitors
por: Xue, Liqiong, et al.
Publicado: (2023)

Ferroptosis Signature Shapes the Immune Profiles to Enhance the Response to Immune Checkpoint Inhibitors in Head and Neck Cancer
por: Chung, Chih‐Hung, et al.
Publicado: (2023)

Epigenetic Alterations and Biomarkers for Immune Checkpoint Inhibitors–Current Standards and Future Perspectives in Malignant Pleural Mesothelioma Treatment
por: Yoshikawa, Yoshie, et al.
Publicado: (2020)

Overview of current and future biologically based targeted therapies in head and neck squamous cell carcinoma
por: Matta, Ajay, et al.
Publicado: (2009)

Current Trends and Future Prospects of Molecular Targeted Therapy in Head and Neck Squamous Cell Carcinoma
por: Kitamura, Naoya, et al.
Publicado: (2020)

Immunotherapeutic Strategies for Head and Neck Squamous Cell Carcinoma (HNSCC): Current Perspectives and Future Prospects
por: Gao, Lei, et al.
Publicado: (2022)

Update of a prognostic survival model in head and neck squamous cell carcinoma patients treated with immune checkpoint inhibitors using an expansion cohort
por: Issa, Majd, et al.
Publicado: (2022)

Chemotherapy following immune checkpoint inhibitors in recurrent or metastatic head and neck squamous cell carcinoma: clinical effectiveness and influence of inflammatory and nutritional factors
por: Sakai, Akihiro, et al.
Publicado: (2023)

Immune-mediated hepatitis induced by immune checkpoint inhibitors: Current updates and future perspectives
por: Liu, Zherui, et al.
Publicado: (2023)

Cerebral Infarction as a Rare Adverse Event of Immune Checkpoint Inhibitors in Patients With Head and Neck Squamous Cell Carcinoma: A Case Series
por: Inoue, Takahiro, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_uq7bhh1vorsr7s1fbtf0127p43